| Outcome Measures: |
Primary: Clinical safety laboratory, Haematology, biochemistry and urinalysis: changes or findings from baseline in clinical safety laboratory parameters during the trial duration (screening visit, treatment visits and follow up visit), Up to 10 weeks|Physical examination, Examination of the body systems, Up to 10 weeks|ECG parameters, Heart rate, PQ, QRS, QT, QTcB: changes or findings from baseline in ECG parameters during the trial duration (screening visit, treatment visits and follow up visit), Up to 10 weeks|Vital signs, Diastolic and systolic blood pressure (mmHg), Pulse (beats/min), Body temperature (°C), Respiratory frequency (RF/min): changes or findings from baseline in vital signs during the trial duration (screening visit, treatment visits and follow up visit), Up to 10 weeks|Adverse events and serious adverse events, Untoward medical occurrence, Up to 10 weeks|Assessments of local tolerability at injection site, Local reaction at injection site, Up to 10 weeks | Secondary: AUCPK 0-30min, area under the baseline adjusted plasma glucagon concentration curve from 0 to 30 min, From 0 to 30 min|AUC PK 0-4h, area under the baseline adjusted plasma glucagon concentration curve from 0 to 4 h, From 0 to 4 hours|ΔAUCPG 0-30min, area under the baseline adjusted plasma glucose curve from 0 until 30 min, From 0 to 30 min|ΔAUCPG 0-4h, area under the baseline adjusted plasma glucose curve from 0 until 4h, From 0 to 4 hours|ΔPG 30min, baseline adjusted plasma glucose concentration at 30 min, From 0 to 30 min|Percentage of patients achieving a plasma glucose increase of ≥20 mg/dL from baseline within 30 minutes after treatment, only at day 2, 30 min after drug administration|Time to plasma glucose increase of ≥20 mg/dL from baseline, only at day 2, Up to 4 hours after drug administration
|
